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While a main feature of HIV-1 pathogenesis is the death
 
of CD4
 
1
 
 T cells due to apoptosis, the mechanisms of apop-
tosis are highly controversial (1, 2). Several HIV-1 proteins
have been implicated in apoptosis regulation, among them
 
viral protein R (Vpr), a small (
 
z
 
14 kD) HIV-1 accessory
protein that is packed in the nucleocapsid through its inter-
action with the Pr55 Gag precursor (3). In addition to its
roles in apoptosis and virus assembly, several other activities
have been ascribed to Vpr–protein interaction, including:
(a) translocation of the HIV-1 preintegration complex
through the nuclear pore, a necessary step for the replica-
tion of HIV-1 in nondividing cells—Vpr appears to partic-
 
ipate in this process by binding to kariopherin 
 
a
 
; (b) induc-
tion of cell cycle arrest, likely by Vpr binding to and
inactivating MOV34, an upstream positive regulator of the
p34–cyclin B complex shown to be essential for the G2–M
phase transition; (c) stimulation of viral gene expression
through physical interaction of Vpr with transcription fac-
tors and/or as a consequence of its effect on cell cycle. The
ability of Vpr to exert so many effects through direct pro-
tein–protein interactions, followed by changes in target
protein activity, can be explained by thinking of Vpr as a
chaperone, as recently suggested by the fact that Vpr can
substitute for hsp70, a cellular chaperone (4). Thus, Vpr
seems to possess structural features that allow for binding to
more than one protein with sufficient energy to cause
changes in activity (presumably in conformation) of target
proteins.
 
In this issue (5), Jacotot et al. extend their previous find-
ing (6) that the mitochondrial adenine nucleotide transloca-
tor (ANT), a proposed component of the permeability
transition pore, constitutes a novel Vpr target. Here, they
present a large number of experiments to test the idea that
this physical interaction of Vpr and ANT is central to Vpr-
induced apoptosis. First, in pure lipid bilayer membranes,
they demonstrate that adding an apoptogenic peptide de-
rived from Vpr (Vpr 52–96) and ANT together leads to
channel formation. The channels they measure could easily
be large enough to permeabilize (although channel selectiv-
ity remains to be determined) the inner mitochondrial
membrane, leading to uncoupling of mitochondrial respira-
tion, loss of transmembrane potential, swelling of the ma-
trix, and release of intermembrane proteins, activities of
Vpr 52–96 that they independently demonstrate on isolated
mitochondria. Second, based on the ability of PA10, a volt-
age-dependent anion channel (VDAC) inhibitor to impair
Vpr binding to mitochondria, they argue that Vpr targets
ANT by passing through VDAC. Third, they show that
Bcl-2 can displace Vpr 52–96 from ANT with recombinant
proteins and that thereby, Bcl-2 can inhibit both the bind-
ing of Vpr to ANT in mitochondrial membranes and the
effects of Vpr on mitochondria. According to Jacotot et al.,
the mechanism of Vpr-induced apoptosis that emerges from
this multidisciplinary approach is as follows (Fig. 1, top
row: Vpr enters the intermembrane space through VDAC,
binds to the intermembrane face of ANT (this is the stage at
which Bcl-2 would inhibit apoptosis), and opens ANT to
permeabilize the inner mitochondrial membrane. This leads
to inner membrane swelling and rupture of the outer mem-
brane to release apoptogenic factors.
While this scheme is attractive, there are alternative hy-
potheses and many details to worry about. If Vpr crosses
the outer mitochondrial membrane through VDAC, this is
very important because Vpr oligomerizes at very low (as
yet undetectable) concentrations, and the lumen of VDAC
is already close to that of an 
 
a
 
 helix (7, 8). More work is
needed to confirm their proposal for the following reasons:
(a) since Vpr binds mitochondrial VDAC (6), the inhibi-
tory effect of PA10 on Vpr binding to mitochondria may
reflect direct binding to VDAC; (b) PA10 generally de-
creases mitochondrial membrane permeability, and PA10
efficiently inhibits pores other than VDAC (our unpub-
lished observations), so PA10 is not specific for VDAC; (c)
NADH does not impair Vpr 52–96 from reaching ANT
despite the fact that NADH induces VDAC closure in ways
similar to those of PA10 (9). As extracellular Vpr crosses
the plasma membrane before gaining access to the mito-
chondria, Vpr can cross membranes through alternative,
VDAC-independent pathways, and these transport mecha-
nisms may be at work in the outer mitochondrial mem-
brane as well (Fig. 1 A, second from top).
The fact that Vpr can cross membranes may be related to
the fact that Vpr is membrane active and perforates lipid bi-
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layers and cell membranes. The electrophysiological re-
cordings of Vpr-induced conductance changes (10–12), be-
ing continuously variable, are more consistent with the
hypothesis that Vpr causes local disturbances of the lipid bi-
layer (lipidic pores; reference 13) by interacting with mem-
brane lipids and proteins (Fig. 1 A, third from top) than the
hypothesis that Vpr forms channels. Vpr could then move
across the monolayer of the lipidic pore (Fig. 1 A, bottom).
As anionic lipids and high negative transmembrane poten-
tials increase poration by a COOH-terminal peptide of Vpr
(12), and since these are features of the inner mitochondrial
membrane, Vpr may itself induce inner mitochondrial
membrane permeabilization, explaining the effects of Vpr
on respiration (if the two inhibitors of Vpr’s action also act
on Vpr’s alternate target) (Fig. 1 B, bottom). One might
think that the ability of Bcl-2 to block Vpr 52–96/ANT
channel formation without binding to the viral peptide
supports the idea that ANT is the essential channel compo-
nent, but perhaps Bcl-2 prevents ANT from promoting
Vpr’s intrinsic poration activity. Jacotot et al. find that Bax
enhances the channel activity of Vpr–ANT, and Bax local-
izes to the outer mitochondrial membrane, so Vpr and en-
dogenous Bax may cooperatively induce outer mitochon-
drial membrane permeabilization. We have recently
proposed that Bax, in association with lipid molecules,
forms pores of variable size in the outer mitochondrial
membrane (13, 14), and this proposal has been extended to
t-Bid (15). Formation and widening of such lipidic pores
should increase with increasing surface tension in the outer
mitochondrial membrane, which is expected as a result of
matrix swelling. In other words, ANT opening would al-
ways facilitate the autonomous pore-forming activity of
Figure 1. Hypothetical interactions of Vpr with outer and inner mitochondrial membranes in the mechanism of Vpr-induced apoptosis. Column A:
Outer membrane mechanisms. First, Vpr is proposed to pass through VDAC (5). Second, Vpr is known to traverse biological membranes autonomously
(7). Third, Vpr may induce lipidic pores, local discontinuities in the lipid bilayer structure of the membrane composed of lipids or lipid and proteins (13).
Fourth, Vpr may traverse a lipidic pore of its own induction. Column B: Inner membrane mechanisms. First, Vpr is shown to bind to ANT and proposed
to cause ANT to change conformation to create a channel in the inner membrane (5). Second, while binding to ANT, Vpr may also interact with inner
membrane or matrix components in as yet unknown ways to cause depolarization and inner membrane swelling. Third, Vpr may induce a lipidic pore in
the inner membrane. Column C: Release of apoptogenic factors. First, inner membrane swelling (secondary to inner membrane permeabilization) rup-
tures the outer mitochondrial membrane, releasing cytochrome c, apoptosis-inducing factor (AIF), second mitochondria-derived activator of caspase/
direct inhibitor of apoptosis proteins (IAP)-binding protein with low pI (Smac/DIABLO), and other intermembrane factors that cause apoptosis (16, 17).
Second, Vpr-induced lipidic pores in the outer membrane can widen, depending on outer membrane surface tension and spontaneous curvature (13).
Note that these putative interactions are not mutually exclusive and may be synergistic. For example, any increased swelling of the inner membrane could
increase surface tension in the outer membrane and widen lipidic pores. Also, the local rupture of the outer membrane caused by swelling-induced ten-
sion is probably a lipidic pore, albeit a wide one. 
F13
 
Basañez and Zimmerberg
 
proapoptotic Bcl-2 family proteins. The proposal by Jaco-
tot et al. that Vpr affects the permeability of the inner be-
fore the outer mitochondrial membrane is hard to judge,
because it is based in the comparison of permeability to
molecules of very different sizes (NADH and H
 
3
 
O
 
1
 
 versus
cytochrome c). Moreover, at low ionic strength, cyto-
chrome c tends to remain attached to inner membranes,
not readily releasable upon outer membrane permeabiliza-
tion. However, all things being equal, and assuming that
Vpr has access to all membranes through its translocation
activity, the membrane-perturbing effects of Vpr will be
detected first by the membrane that is tight, the inner
membrane, rather than the outer membrane, which is al-
ready comparatively leaky. Thus, inner membrane perme-
abilization may be the dominant effect in Vpr-induced ap-
optosis as well (though not for other apoptogenic stimuli
that deplete intermembrane cytochrome c without perme-
abilizing the inner membrane) (16, 17). Electrophysiologi-
cal studies of the effect of Vpr on wild-type and VDAC/
ANT-deficient mitochondrial membranes might provide
further insight on the exact role of these proteins on mito-
chondrial membrane permeabilization.
Strikingly, Vpr can not only cause apoptosis but can also
inhibits apoptosis (18–20)! It has been proposed that Vpr-
induced apoptosis occurs at the relatively large concentra-
tions of Vpr seen during active viral replication, while low
Vpr concentrations at the onset of infection inhibit the host
apoptotic response to help ensure prolonged viral replica-
tion, as in many other viruses (21). Perhaps the antiapop-
totic activity exerted by Vpr is also due to its mitochondrial
localization. Vpr may maintain VDAC in an open configu-
ration to facilitate nucleotide exchange across the outer mi-
tochondrial membrane, similar to that proposed for Bcl-2
and Bcl-x
 
L
 
 (22). Thus, the antiapoptotic effects of Vpr may
be exerted through a VDAC-mediated mitochondriopro-
tective effect, while the proapoptotic effects of Vpr may be
mediated through both its ability to perturb mitochondrial
membranes and its more specific ANT-mediated effects.
The work of Jacotot et al. provides a framework for further
testing these mechanisms.
Whatever the in vitro mechanisms of apoptosis, it is the
in vivo mechanisms that are the most important. While iso-
lated PBMCs from HIV-1–infected individuals do not un-
dergo apoptosis at either an increased or a decreased rate,
they are much more susceptible to apoptotic stimuli (1, 2).
This is understandable in terms of the properties of Vpr dis-
cussed above, which would be synergistic with other stim-
uli to promote apoptosis. But why should HIV-1 want to
promote apoptosis? It is possible that Vpr acts as a necessary
brake on HIV-1 replication by removing productively in-
fected T cells through apoptosis induction, to prevent pre-
mature T cell burnout and rapid disease progression to host
death. The antiapoptotic function of Vpr is easier to under-
stand, as it ensures continuance of viral production by in-
fected cells. Also, the antiapoptotic function of Vpr may
play a role in the incomplete eradication of HIV by current
therapies. In spite of highly active antiretroviral therapy
(HAART), HIV-1 continues to reside in resting memory
 
CD4
 
1
 
 T cells and to replicate at low levels in undefined
cells (23–25). Perhaps the antiapoptotic effects of Vpr lead
to the preservation of a pool of infected cells constitutively
expressing Vpr at low levels. In support of this idea, it has
recently been found that Vpr is not structurally or func-
tionally inactivated in latently infected CD4
 
1
 
 T cells of
patients on HAART (26). We propose that Vpr plays a
prominent role in maintaining HIV-1 reservoirs through its
antiapoptotic activity, and the idea of reversing this activity
to promote the proapoptotic activity of Vpr discussed in
this issue might make the reservoir cells more vulnerable to
therapeutic attack.
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